Kornimate/medical-research-clean huggingface dataset:
correlation between beliefs about medicine and objective measures of efficacy and safety in rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: it can be assumed that there is a link between what the patient feels and thinks about his medication and objective measures of disease activity and safety.

a total of 500 subjects will provide 80% power to test the hypothesis that the absolute value of the correlation between two measures (e.g., bmq necessity and das28) is ≤ 0.3 (i.e., h0:│r│ ≤ 0.3 ) versus the alternative that it is \> 0.3 (i.e., h1:│r │ \> 0.3 ) assuming the absolute value of the true correlation is 0.40. a total of 500 will be enrolled to allow for approximately 5% being lost from analysis due to lack of post baseline data. the pearson method will be used for correlation between the bmq total score for necessity and the das28 and between the bmq total score for concern and das28. the spearman rank method will be used for correlation between the bmq total scores and safety. for these latter analyses, subjects will be classified into one of 3 safety categories: (1) no aes, (2) non-serious aes, (3) serious aes. 95% confidence intervals for the correlations will be provided.

Eligibility criteria:
inclusion criteria: patients with ra on stable therapy defined as: etanercept: 1x50 mg/week or 2x25mg/week for at least 1 consecutive year. adalimumab: 1x40 mg every other week for at least 1 consecutive year. oral corticosteroids: stable doses for ≥ 12 weeks before baseline methotrexate: stable doses for ≥ 12 weeks before baseline other dmard's: stable doses for ≥ 12 weeks before baseline exclusion criteria: participation in other clinical or observational trials.
pronostic score of morbidity to determine risk of complications after endoscopic submucosal dissection for colorectal lesions

Conditions: Polyp of Colon

Summary: the mains complications in colo-rectal dissection are the pain, the delayed bleeding and the perforation and represent around 10%. currently, the procedure is realized during a hospitalization with not real recommendation about the time of this. there is currently no score established for the colo-rectal endoscopic submucosal dissection. * to develop clinical or mixed prognostic score after endoscopic subcostal dissection for colorectal lesions in nancy's hospital. * allow to obtain an estimation of number of patients required for a larger study.


Eligibility criteria:
inclusion criteria: * patient suffering of lesion relevant of endoscopic submucosal dissection treatment: * lesions for which en bloc resection with snare emr is difficult to apply i/lst-ng, particularly lst-ng (pd) ii/ lesions showing a vi-type pit pattern iii/ carcinoma with shallow t1 (sm) invasion large depressed-type tumors iv/ large protruded-type lesions suspected to be carcinoma * mucosal tumors with submucosal fibrosis * sporadic tumors in conditions of chronic inflammation such as ulcerative colitis * local residual or recurrent early carcinomas after endoscopic resection local res les lésions de plus * male or female patients aged ≥ 18 years old * patients able to fill in questionnaires written in french exclusion criteria: * suspicion of deep submucosal cancer by analysis of macroscopic appearance (paris o-iii), vascular pattern and pit pattern (sano iiib, kudo vn)

Keywords: endoscopic submucosal dissection
pet-mr for prediction and monitoring of response to neoadjuvant chemotherapy in breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is: to validate the efficacy of multiparametric mri, fdg-pet, rgd-pet, and pet-mr fusion imaging in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients. to identify the optimal combination parameters of mr spectroscopy, diffusion-weighted mri, dynamic contrast-enhanced mri, fdg-pet, and rgd-pet in the prediction and monitoring response to neoadjuvant chemotherapy of locally advanced breast cancer patients. to compare the performances of dynamic contrast-enhanced mri using parametric response map analysis versus those of pharmacokinetic parameters (ktrans, kep, or ve) in the early prediction of pathological responsiveness to neoadjuvant chemotherapy in breast cancer patients

enrolled women with breast cancers who had received an anthracycline-taxane regimen and subsequent surgery were prospectively enrolled. dce-mri and fdg-pet scan were performed before and after the 1st cycle of chemotherapy. mr imaging parameters and suv on pet scan within a tumor were analyzed. clinicopathologic (age, clinical tumor stage, hormonal receptor status, and surgery type) and imaging parameters were compared according to the pathological response.

Eligibility criteria:
inclusion criteria: * pathologically confirmed breast cancer * clinical stage iib, iiia, iiib, iiic * must have measurable disease * performance status of ecog 0-2 * adequate, bone marrow, liver, heart, and renal function * who did not receive chemotherapy for breast cancer * must agree with and signed informed consent exclusion criteria: * prior history of cancer besides breast cancer * active bacterial infection * pregnant or lactating women * psychological disease or seizure * history of arrhythmia, congestive heart failure, myocardial infarct, or unstable angina * male breast cancer * who had a pacemaker or history of open heart surgery

Keywords: magnetic resonance imaging, functional tomography, positron-emission chemotherapy
evaluation of web-based interventions to support people living with hiv in the adoption of health behaviors

Conditions: HIV

Summary: the purpose of this study is to evaluate the efficacy of a web-based tailored intervention to support persons living with hiv (plhiv) manage the demands inherent to their health condition, particularly as regards to the adoption of health behaviours such as being physically active, following a healthy diet and quitting smoking. this randomized controlled trial is currently conducted entirely online at www.lhivehealthy.ca

this online randomized controlled trial with parallel-groups is conducted across canada. interested participants are invited to visit the study's website at www.lhivehealthy.ca the study's website contains video clips explaining the study. after accepting the conditions and consenting, participants will enroll in the study by providing an email address and a pseudonym. each participant will be validated through an email address check. after their enrolment, participants will receive a hyperlink via email to invite them to complete a baseline questionnaire. after completing the baseline questionnaire, participants will be randomly assigned by the computer system either to an experimental group (tavie en santé) or to a control group (list of 5 websites). three and six months after the baseline questionnaire, participants will complete the online questionnaires again.

Eligibility criteria:
inclusion criteria: * to be living with hiv * to be able to read and understand french or english * to have access to the internet

Keywords: tailored web-based intervention health behavior hiv comorbidities online trial
myofunctionnal therapy on nasal breathing and orthodontic corrections stability

Conditions: Mouth Breathing; Atypic Swallowing; Low Resting Position of Tongue

Summary: the current research project aims to study the efficacy of myofunctional therapy and its orthodontic long-term outcomes.

the current research project aims to study the efficacy of myofunctional therapy and its orthodontic long-term outcomes, such as: 1) is treating a low tongue position and lip closure at rest sufficient for orthodontic short and long-term outcomes? 2) does treating atypical swallowing along with an incorrect tongue position help achieve and maintain higher outcomes of the myofucntional and orthodontic treatments?

Eligibility criteria:
inclusion criteria: * between 6 and 14 years old * atypical or immature swallowing pattern and lower position of the tongue at rest * be an orthodontic patient treated at the faculty of dentistry, université de montreal * speak and understand french without assistance * be in good health (without neurological or psychiatric syndrome) * agree to participate and sign the consent form research exclusion criteria: * non compliance to clinical visits (eg too many missed visits) * patients who had previous orthodontic treatments * syndrome or known systemic disease (chronic cardiopulmonary or neuromuscular disease, dysmorphia, major craniofacial abnormalities)
improving outcomes in cancer patients with a nutritional and physical conditioning prehabilitation program

Conditions: Pancreatic Cancer; Liver Cancer; Bile Duct Cancer; Hepatobiliary Cancer; Surgery

Summary: major surgery is a stressful procedure; good recovery after surgery is important to patients and their doctors. studies done at the mcgill university health centre (muhc) with cancer patients awaiting surgery have shown that exercise combined with simple diet recommendations (which may include a supplement) and relaxation techniques before surgery helped speed up the ability to resume walking after surgery. these results have made the investigators aware that exercise and good nutrition are as important before surgery as they are after surgery; while it is common practice to start strengthening the body after surgery (rehabilitation), there may be some advantage to begin this process before surgery (prehabilitation). the purpose of this study is to see if the following program, either before or after surgery, can help patients recover from liver, pancreas or bile duct surgery: 1. exercise that may help participants move and breath better, 2. nutrition advice and a supplement to make participants strong, 3. relaxation and anti-anxiety tips to help cope with the stress of upcoming surgery the investigators will see if following this program will have an effect on participants' ability to walk before and after surgery.


Eligibility criteria:
inclusion criteria: * a diagnosis or suspicion of either hepatobiliary or pancreatic cancer (primary or metastatic) * must be scheduled for surgical resection between 4-6 weeks of recruitment exclusion criteria: * persons with american society of anesthesiologists (asa) health status class 4-5 * comorbid medical, physical and mental conditions (eg: dementia, disabling orthopedic and neuromuscular disease, psychosis) * cardiac abnormalities * severe end-organ disease such as cardiac failure, chronic obstructive pulmonary failure and hepatic failure (alanine aminotransferase and aspartate aminotransferase \>50% over the normal range) * sepsis * morbid obesity (bmi \>40) * anemia (hematocrit \<30 %) * other conditions interfering with the ability to perform exercise at home or to complete the testing procedures * poor english or french comprehension

Keywords: nutrition exercise relaxation techniques prehabilitation
effects of phytoestrogen from pueraria mirifica in improvement of serum lipid parameters in postmenopausal women

Conditions: Dyslipidemias; Hypertriglyceridemia; Hypercholesterolemia; Hyper-LDL-cholesterolemia; Hypo HDL Cholesterolaemia; Postmenopausal Symptoms

Summary: the goal of this clinical trial is to learn about the effects of phytoestrogen from pueraria mirifica in improvement of serum lipid parameters. the primary question it aims to answer are: • phytoestrogen from pueraria mirifica can reduce serum triglyceride, total cholesterol, ldl and increase hdl or not participants will receive capsules which composed of dry weight 50 mg of pueraria mirifica twice a day for 2 months. researchers will compare with diet control\&life style modification to see if there is the improvement of serum lipid parameters

the secondary question it aims to answer are: * phytoestrogen from pueraria mirifica can reduce menopausal symptom score or not * phytoestrogen from pueraria mirifica can reduce body mass index(bmi) or not * phytoestrogen from pueraria mirifica can reduce waist circumference or not * phytoestrogen from pueraria mirifica can reduce blood pressure or not * phytoestrogen from pueraria mirifica effects to creatinine, bun, egfr or not * phytoestrogen from pueraria mirifica effects liver function enzymes or not

Eligibility criteria:
inclusion criteria: 1. natural menopause, last menstrual period more than one year ago. 2. abnormal lipid profile parameters the criteria set for this research are: * ldl\>130 mg/dl or * tg\>150 mg/dl or * total cholesterol\>200 mg/dl or * hdl-c less than 50 mg/dl. (latest blood results not more than 6 months) 3. willing to participate in the project exclusion criteria: 1. have ever received lipid-lowering medication or hormone replacement therapy or serms. during the past 6 weeks 2. have had surgery on the ovaries or uterus before 3. have a history of cancer within a 5-year period 4. have diabetes or uncontrolled high blood pressure, including hba1c \>9, systolic blood pressure \>180 or diastolic blood pressure \>110 5. endocrine system disease such as thyroid 6. ever had an organ transplant 7. regularly use drugs, marijuana, or drink alcohol. 8. has a psychiatric disorder 9. have other serious medical conditions that require close monitoring 10. inconvenient to follow up until the end of the research.

Keywords: phytoestrogens pueraria mirifica postmenopausal women dyslipidemia hypertriglyceridemia hypercholesterolemia hyper-ldl-cholesterolemia hypo hdl cholesterolaemia postmenopausal symptoms randomized clinical trail
diabetic patients needs in therapeutic education about work. te-diw (therapeutic education of diabetic working people)

Conditions: Diabetes Mellitus, Type 1

Summary: diabetes mellitus is an important disease around the world and the number of diabetic people increase every day. the type 1 diabetes often occurred in the youth and people have to learn to work with it and its complication. conversely, diabetic people sometimes have trouble to manage their diabetes with working obligation. actually, french therapeutic education don't teach how to reconcile diabetes and work. the study hypothesis is that type 1 diabetic people can be helped by therapeutic education in order to reconcile the management of their diabetes and their work. this study is a qualitative study. interviews will help to find the needs of the type 1 diabetic patients to reconcile diabetes and work.


Eligibility criteria:
inclusion criteria: * age\>18 years old * to be diagnosed with type 1 diabetes according to the criteria of the french high authority of health and confirmed by an endocrinologist * to have paid employment with an employment contract during the study * to be informed and having no opposition to the study exclusion criteria: * self-employed person * to be unemployed * to be diagnosed with an other disease wich could damage cognition or motricity and could interfere with work (cancer, neurodegenerative disorder, etc) * to have legal guardian.
citrate anticoagulation for postdilution hemofiltration

Conditions: Acute Kidney Injury; Critical Illness

Summary: this study evaluates a protocol for regional citrate anticoagulation in critically ill patients with acute kidney injury who are treated with continuous veno-venous haemofiltration in postdilution mode.

acute kidney injury (aki) requiring continuous renal replacement therapy (ccrt occurs in approx. 15 % of all intensive care patients. a sustained and prolonged filter running time is required to deliver an effective dialysis dose. this requires effective anticoagulation. today, regional citrate anticoagulation (rca) is preferred over systemic anticoagulation because of prolonged filter lifetimes and less adverse effects. we here study prospectively patients with aki who are treated with continuous veno-venous haemofiltration using an rca protocol. we will evaluate all parameters of crrt including filter running times, delivered dialysis dose, causes for treatment interruption and control of ph and electrolytes.

Eligibility criteria:
inclusion criteria: * acute kidney injury * critical illness and treatment at icu exclusion criteria: * age \< 18 years * pregnancy or breast feeding * severe lactate acidosis ( \> 10 mmol/l) for longer than 6 hours and ph \< 7.2
treatment patterns with brolucizumab in germany - a retrospective cohort study based on longitudinal prescription data: realize study

Conditions: Neovascular Age-related Macular Degeneration

Summary: realize was a single-arm retrospective cohort study which described treatment patterns with brolucizumab, including treatment intervals between anti-vascular endothelial growth factor (vegf) injections before and after a switch to brolucizumab. this study was conducted using german patient-level prescription data and the prescription date was used as a proxy for anti-vegf injection date. the study period was defined from the date of the first available anti-vegf injection in the dataset to 30 november 2021. the index date for each patient was the date of the first brolucizumab injection, which could be anytime between 01 march 2020 (since brolucizumab became available in germany for use outside of clinical trials in march 2020) and 30 november 2021. the date of the patient's first neovascular age-related macular degeneration (namd) diagnosis was assumed to be the date of the first anti-vegf prescription in the database for that patient, from january 2015 onwards.


Eligibility criteria:
inclusion criteria: • patients aged ≥50 years with a namd diagnosis, who received ≥1 brolucizumab prescription regardless of prior anti-vegf treatment, and had a minimum of 12-month follow-up from index date. exclusion criteria: * patients without a record of prescription of any drug in the six months before the index date (pre-index period). * patients with evidence of bilateral treatment with brolucizumab.
cost-effectiveness study of symbicort as maintenance and reliever therapy (smart)

Conditions: Asthma

Summary: this study is an economic evaluation of symbicort (budesonide/formoterol) as maintenance and reliever therapy (smart) versus its competitive alternatives. the aims of this study are: * to estimate the relative effectiveness of each one of the alternatives in the management of patients with moderate to severe asthma through a systematic review for the following outcomes: * cumulative incidence of asthma severe exacerbations symptoms * safety of each alternative (frequency of adverse events and complications due to the medications) * to estimate the direct medical costs of treating with each pharmacologic alternative: symbicort as smart versus increased use of inhaled corticosteroids or adding long-acting inhaled beta 2 agonist plus inhaled corticosteroids. * to create a decision analysis model (decision tree) that allows comparisons between the alternatives on expected values and costs. * to calculate the average and incremental cost-effectiveness ratios. * to carry out a sensitivity analysis to test de robustness of the cost-effectiveness results allowing for reasonable changes in expected values and costs.


Eligibility criteria:
inclusion criteria: * moderate to severe asthma.

Keywords: cost-effectiveness analysis symbicort
metaphyseal distal radius fractures

Conditions: Metaphyseal Radius Fractures (AO Type A2, A3, C1 et C2)

Summary: the number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. several surgical techniques are described in particular locking plates and intrafocal pinning techniques. the aim of the study is to compare (x-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis.

because an increasing number of elderly patient, the number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. several surgical techniques exist of which in particular locking plates and intrafocal pinning. the availability of new materials (locking plates with angular stability) seems to reduce the risks of osteosynthesis failure and seems to give more constant results: hawever, the price to pay is a more invasive technique and a superior cost. the rehabilitation seems also faster, allowing the possibility to get back the maximum of autonomy. these clinical facts need of course to be validated.

Eligibility criteria:
inclusion criteria: * - metaphyseal inferior radius fractures (ao classification 23a2, 23a3, 23c1, 23c2) * age 60 years or older exclusion criteria: * open fracture * fractures ao classification: 23a1, 23c3, 23b1, 23b2, 23b3 * polytraumatized patient * fractures older than 15 days * infection of the operating site * previous osseous disease

Keywords: fracture radius osteosynthesis metaphyseal pinning locking anterior plate
mesenchymal stem cell transplantation in ms

Conditions: Multiple Sclerosis

Summary: the study is a randomized phase ii study, masked and crossed-over with placebo to evaluate the safety and tolerability of autologous mesenchymal stem cell transplantation in patients with active multiple sclerosis


Eligibility criteria:
inclusion criteria: 1. inflammatory forms of ms 1. relapsing-remitting ms (rrms) patients 2. secondary progressive ms (spms) patients with continued relapses 3. primary progressive ms (ppms) patients with enhancing mri lesions and positive csf (oligoclonal banding) 2. age 18-50 years 3. disease duration \>= 2 and \>= 10 years 4. edss 3.0 - 6.5 5. progression, continued relapses or worsening mri after at least a year of attempted therapy evidenced by: 1. increase of \>= 1 edss point (if baseline edss \ = 5.5), or quantifiable, objective evidence of equivalent progression 2. \>= 1 moderate-severe relapses in past 18 months 3. \>= 1 gadolinium enhancing lesions (double or triple dose gadolinium) 4. \>= 1 new t2 lesion 5. for ppms only, \>= 1 gadolinium enhancing lesions 6. has given informed consent to participate in the study. exclusion criteria: 1. spms without ongoing relapses 2. ppms without positive csf or gadolinium enhancing lesions 3. \<= 3 months since treatment with any immunosuppressive therapy 4. \<=1 month since last treatment with interferon-b or glatiramer acetate 5. corticosteroid treatment \<= 30 days 6. relapse \<= 60 days 7. history of cancer or clinical or laboratory results indicative of severe systemic diseases, including infection for hiv, hepatitis b or c 8. any metallic or electronic device that precludes from undergoing mri 9. pregnancy or lactation 10. current treatment with an investigational therapy

Keywords: multiple sclerosis